Tyme and JAF Announce Sarcoma Treatment Collaboration

NEW YORK, April 06, 2018 -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company, today announced that it is collaborating with The Joseph Ahmed Foundation (“JAF”) to provide treatment for metastatic sarcomas. The collaboration will focus on children and young adults with bone or soft tissue sarcomas, with an initial focus on Ewing's sarcoma. Sarcomas are rare forms of cancer that have poor prognosis at the metastatic stage, with most treatment options demonstrating limited efficacy and high toxicity. 

Two Ewing's sarcoma patients have previously been treated with Tyme’s SM-88 therapy under compassionate use programs, both of whom achieved a complete or partial response with no drug-related severe adverse events. Under this new collaboration, Tyme will supply SM-88 at no cost and JAF will provide resources for physicians to perform investigator-sponsored trials.

“JAF was founded to honor the memory of our son, Joseph, by fundraising for research and helping discover new treatments for sarcoma that will allow young people to feel young rather than like cancer patients,” said Junny Ahmed, Co-Founder of JAF. “Joseph had metastatic Ewing's sarcoma and was very sick after treatment on chemotherapy. We were told he had limited to no therapeutic options. He started SM-88 monotherapy and not only had a partial response, but also felt well enough to participate in a 'Steps for Joe's Cure’ walk (a fundraising event in Joseph's honor) and attend his prom. At a minimum, we just want to give other families that same opportunity.”

JAF and Tyme will be also participating in the April 2018 New Jersey marathon in honor of Joe's Cure Walk and to raise money for sarcoma research.

About The Joseph Ahmed Foundation: Our mission at the Joseph Ahmed Foundation is to promote the treatment and cure of Ewing’s Sarcoma as well as other childhood Sarcomas by: Funding research that may discover the root causes of pediatric cancer; Promoting the development of effective pediatric cancer treatments that will increase survival rates and ultimately provide a cure; Developing public awareness of pediatric cancer detection, prevention, and treatment; Providing support services and essential information to pediatric cancer patients, their families and loved ones.

For more information, visit https://www.thejosephahmedfoundation.org

About Tyme & SM-88

Tyme Technologies, Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types, while having a low toxicity profile. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a novel combination therapy currently in Phase II development for pancreatic and prostate cancer. For more information, see www.tymeinc.com.

Ryan Shucard
202-557-8184
[email protected]